Compare with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS vs SUVEN LIFE SCIENCES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN PHARMACEUTICALS SUVEN LIFE SCIENCES SUVEN PHARMACEUTICALS/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 39.4 -10.3 - View Chart
P/BV x 10.8 16.4 65.7% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 SUVEN PHARMACEUTICALS   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    SUVEN PHARMACEUTICALS
Mar-21
SUVEN LIFE SCIENCES
Mar-21
SUVEN PHARMACEUTICALS/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs525109 481.9%   
Low Rs10319 531.8%   
Sales per share (Unadj.) Rs39.71.1 3,745.7%  
Earnings per share (Unadj.) Rs12.1-5.7 -213.9%  
Cash flow per share (Unadj.) Rs13.4-5.3 -250.9%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs46.45.6 830.5%  
Shares outstanding (eoy) m254.57127.28 200.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x7.960.6 13.1%   
Avg P/E ratio x25.9-11.3 -228.8%  
P/CF ratio (eoy) x23.5-12.0 -195.1%  
Price / Book Value ratio x6.811.5 58.9%  
Dividend payout %16.50-   
Avg Mkt Cap Rs m79,9538,168 978.8%   
No. of employees `000NANA-   
Total wages/salary Rs m762185 411.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,097135 7,491.6%  
Other income Rs m14278 183.6%   
Total revenues Rs m10,240212 4,822.7%   
Gross profit Rs m4,430-799 -554.2%  
Depreciation Rs m31643 727.9%   
Interest Rs m1179 1,239.6%   
Profit before tax Rs m4,139-775 -534.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,053-53 -1,978.8%   
Profit after tax Rs m3,086-722 -427.7%  
Gross profit margin %43.9-593.1 -7.4%  
Effective tax rate %25.46.9 370.4%   
Net profit margin %30.6-535.3 -5.7%  
BALANCE SHEET DATA
Current assets Rs m6,6651,966 339.1%   
Current liabilities Rs m3,2151,098 292.8%   
Net working cap to sales %34.2643.8 5.3%  
Current ratio x2.11.8 115.8%  
Inventory Days Days2002 8,609.9%  
Debtors Days Days370477 77.6%  
Net fixed assets Rs m9,097257 3,534.5%   
Share capital Rs m255127 200.0%   
"Free" reserves Rs m11,554584 1,979.8%   
Net worth Rs m11,808711 1,661.1%   
Long term debt Rs m3564 9,056.2%   
Total assets Rs m15,7622,223 709.0%  
Interest coverage x36.5-81.3 -44.9%   
Debt to equity ratio x00 545.2%  
Sales to assets ratio x0.60.1 1,056.6%   
Return on assets %20.3-32.0 -63.4%  
Return on equity %26.1-101.5 -25.7%  
Return on capital %35.0-107.1 -32.7%  
Exports to sales %069.1 0.0%   
Imports to sales %0547.1 0.0%   
Exports (fob) Rs mNA93 0.0%   
Imports (cif) Rs mNA737 0.0%   
Fx inflow Rs m9,90293 10,637.3%   
Fx outflow Rs m1,369737 185.7%   
Net fx Rs m8,533-644 -1,324.5%   
CASH FLOW
From Operations Rs m3,834-960 -399.3%  
From Investments Rs m-3,114558 -557.7%  
From Financial Activity Rs m-766349 -219.6%  
Net Cashflow Rs m-45-53 84.7%  

Share Holding

Indian Promoters % 60.0 60.0 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 13.8 0.9 1,572.7%  
FIIs % 8.0 0.4 1,825.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 40.0 100.0%  
Shareholders   96,532 81,475 118.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN PHARMACEUTICALS With:   IND. SWIFT  GUJ.TERC LAB  BDH INDUS.  LAURUS LABS   GODAVARI DRU  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

SUVEN LIFE SCIENCES 2020-21 Annual Report Analysis (Annual Result Update)

Nov 18, 2021 | Updated on Nov 18, 2021

Here's an analysis of the annual report of SUVEN LIFE SCIENCES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE SCIENCES. Also includes updates on the valuation of SUVEN LIFE SCIENCES.

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of SUVEN PHARMACEUTICALS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN PHARMACEUTICALS. Also includes updates on the valuation of SUVEN PHARMACEUTICALS.

More Views on News

Most Popular

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN PHARMACEUTICALS SHARE PRICE


Nov 26, 2021 (Close)

TRACK SUVEN PHARMACEUTICALS

  • Track your investment in SUVEN PHARMACEUTICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS - SANOFI INDIA COMPARISON

COMPARE SUVEN PHARMACEUTICALS WITH

MARKET STATS